Goldschmidt H, Moreau P, Ludwig H, et al. Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study. Leuk Lymphoma. 2018, 59(6):1364-1374. doi: 10.1080/10428194.2017.1376743.

home / authors / goldschmidt-h-moreau-p-ludwig-h-et-al-carfilzomib-dexamethasone-versus-subcutaneous-or-intravenous-bortezomib-in-relapsed-or-refractory-multiple-myeloma-secondary-analysis-of-the-phase-3-endeavor-study-leuk-lymphoma-2018

Articles

Study Summary: Carfilzomib + Dexamethasone Versus Bortezomib (SC or IV) + Dexamethasone in Relapsed or Refractory Multiple Myeloma (ENDEAVOR Secondary Analysis)

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777